Skip to content

Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review.

Vivian W L Tsang, Brendan Tao, Shannon Dames, Zach Walsh, Pam Kryskow

Therapeutic advances in psychopharmacology January 1, 2023 DOI: 10.1177/20451253231171512 via PubMed

Summary

AI-generated from the abstract

A retrospective chart review of 128 participants in a 12-week ketamine-assisted group therapy program found that the treatment was well tolerated, with no dropouts. Across 448 sessions, elevated blood pressure occurred after 49.16% of sessions, while nausea affected 12.05% of participant-sessions, vomiting 2.52%, headache 3.35%, and dizziness in seven participant-sessions. Adverse events were transient and resolved with rest or medication. The findings suggest good safety and tolerability for intramuscular and sublingual ketamine dosing in a community group psychotherapy setting.

Study at a glance

Characteristics Retrospective chart review Peer reviewed
Sample size 128
Population Participants in the Roots To Thrive ketamine-assisted therapy program seeking treatment for mental health issues
Intervention group psychotherapy
Duration 12-week program with three ketamine medicine sessions
Topics Depression Ketamine
Keywords Group therapy Psychedelic Psychotherapy
Citations 19
Key finding Intramuscular and sublingual ketamine in a group psychotherapy setting was well tolerated, with no dropouts and only transient adverse events.

Abstract

In the last few years, ketamine is becoming increasingly common in the treatment of mental health conditions, but there is a lack of safety data informing intramuscular and sublingual dosing in a community-focused group psychotherapy setting. The Roots To Thrive ketamine-assisted therapy (RTT-KaT) program is a unique 12-week RTT-KaT program with 12 community of practice (a form of group therapy) sessions and three ketamine medicine sessions. This study reports on adverse effects of intramuscular and sublingual ketamine dosing in a community group psychotherapy setting among 128 participants across four cohorts. Retrospective chart review. A chart review of the RTT-KaT Program was performed retrospectively on four cohorts (n = 128) that participated in 448 sessions running between September 2020 and December 2021. Baseline characteristics and adverse events were captured including medication administration before, during, and after RTT-KaT sessions. Analyses by session and by individual were conducted. Chi-square test with Yates' continuity correction was used to assess side effects in subgroups from ketamine administration. RTT-KaT was well tolerated with none of the 128 participants dropping out of the program. Primarily, of the 448 sessions, 49.16% had elevated blood pressures post-KaT session by session. In terms of other adverse effects, 12.05% of participant-sessions experienced nausea, 2.52% had an episode of vomiting, 3.35% had a headache, and seven participant-sessions experienced dizziness. Analysis by individual revealed congruent findings. These findings suggest good safety and tolerability for RTT-KaT among individuals seeking treatment for mental health issues. The majority of participants did not experience adverse reactions and the adverse events that were recorded involved transient symptoms that were resolved with rest and/or medications. The group therapy model described provides a comprehensive approach and presents a promising model for operating a KaT program in a community setting.

Explore topics

Comments

No comments yet.

Log in to comment